Evidence map›Paper›PMID 39465009›Full record

ArticleExploration of targeted anti-tumor therapy2024

Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy.

Min Woo Hwang, Jasmine Kauffeld, Sarah Belay, Joep J de Jong, Elai Davicioni, Wenping Li, Jeanny B Aragon-Ching

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Exploration of targeted anti-tumor therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Min Woo HwangDepartment of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA 22031, USA.
Jasmine KauffeldMasters of Public Health Program, University of Virginia, Charlottesville, VA 22903, USA.
Sarah BelaySchool of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
Joep J de JongDepartment of Urology, Erasmus University Medical Center, 3015GD Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-2378-367X
Elai DavicioniVeracyte Inc, Decipher Biosciences, San Diego, CA 92121, USA.ORCID https://orcid.org/0000-0001-9136-099X
Wenping LiDepartment of Pathology, Inova Fairfax Hospital, Fairfax, VA 22031, USA.
Jeanny B Aragon-ChingGU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA.ORCID https://orcid.org/0000-0002-6714-141X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Upper tract urothelial cancer (UTUC) are rare subsets of urothelial cancer, which typically present with more aggressive course. Molecular markers stratifying urothelial tumors as luminal subtype and non-luminal subtype tumors have been proposed to select patients who may have greater or lesser benefit from neoadjuvant systemic therapy in bladder cancer, though not yet evaluated in UTUC. Here, a single-institution study retrospectively obtained clinical and genomic information in patients with UTUC and evaluated four patient tumors using the Decipher Bladder

Indexed as

Decipher Bladder®molecular subtypesneoadjuvant chemotherapyUpper tract urothelial cancers

Identifiers

PMID39465009
PMCPMC11502078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.